Shuhang Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shuhang Xu has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Chao Liu
Affiliated Hospital of Integrated Traditional Chinese and Western Medicine Nanjing University of Chinese Medicine Nanjing Jiangsu Province China
15 shared publications Guofang Chen
Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
15 shared publicationsChao Liu
Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
13 shared publicationsXingjia Li
11 shared publicationsXue Han
Department of Endocrinology and Metabolism, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine 1
10 shared publicationsXiaoqiu Chu
Endocrine and Diabetes Center, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine; Jiangsu Province Academy of Traditional Chinese Medicine
8 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 36242
Experiences of a food-based very low-calorie diet programme among Chinese adults with obesity and prediabetes or type 2 diabetes: a COM-B-guided qualitative study
- 31 October 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 36242
Open AccessExperiences of a food-based very low-calorie diet programme among Chinese adults with obesity and prediabetes or type 2 diabetes: a COM-B-guided qualitative study
- Open Access
- 5 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Efficacy and safety of ultrasound-guided microwave ablation for primary hyperparathyroidism: a dual-centre study
This study aimed to evaluate the efficacy and safety of ultrasound-guided microwave ablation (MWA) for the treatment of primary hyperparathyroidism (PHPT). This study enrolled 46 patients with PHPT from two centers between July 2019 and January 2024. The primary end point was clinical success, defined as the achievement of normal levels of both intact parathyroid hormone (iPTH) and serum calcium at 6 months post-MWA (40/46). Secondary end points were technical success and procedure-related complications, with the former defined as the achievement of complete ablation. The clinical and technical success rate were 87.0% (40/46) and 100.0% (56/56), respectively. Serum iPTH, calcium and phosphorus showed significant improvement within the 6 months post-MWA [iPTH, 156.6 (114.3-241.0) pg/mL vs. 58.3 (49.0-62.4) pg/mL; calcium, 2.70 ± 0.30 mmol/L vs. 2.38 ± 0.11 mmol/L; phosphorus, 0.86 ± 0.19 mmol/L vs. 1.01 ± 0.17 mmol/L, respectively; all, p < 0.01]. The 6-month volume reduction rate (VRR) was 79.0%, and no long-term complications were observed during follow-up. These results suggest that ultrasound-guided MWA is a safe and effective non-surgical alternative for the management of PHPT.
- 5 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessEfficacy and safety of ultrasound-guided microwave ablation for primary hyperparathyroidism: a dual-centre study
This study aimed to evaluate the efficacy and safety of ultrasound-guided microwave ablation (MWA) for the treatment of primary hyperparathyroidism (PHPT). This study enrolled 46 patients with PHPT from two centers between July 2019 and January 2024. The primary end point was clinical success, defined as the achievement of normal levels of both intact parathyroid hormone (iPTH) and serum calcium at 6 months post-MWA (40/46). Secondary end points were technical success and procedure-related complications, with the former defined as the achievement of complete ablation. The clinical and technical success rate were 87.0% (40/46) and 100.0% (56/56), respectively. Serum iPTH, calcium and phosphorus showed significant improvement within the 6 months post-MWA [iPTH, 156.6 (114.3-241.0) pg/mL vs. 58.3 (49.0-62.4) pg/mL; calcium, 2.70 ± 0.30 mmol/L vs. 2.38 ± 0.11 mmol/L; phosphorus, 0.86 ± 0.19 mmol/L vs. 1.01 ± 0.17 mmol/L, respectively; all, p < 0.01]. The 6-month volume reduction rate (VRR) was 79.0%, and no long-term complications were observed during follow-up. These results suggest that ultrasound-guided MWA is a safe and effective non-surgical alternative for the management of PHPT.
- Open Access
- 22 April 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1773527
Ultrasound-guided microwave ablation for small thyroid nodules with RAS mutation: a pilot study
Objective: The clinical management of RAS-mutated nodules faces significant challenges. This study aimed to explore the efficacy of microwave ablation (MWA) for the treatment of thyroid nodules ≤ 2 cm with isolated RAS gene mutations. Methods: This retrospective study was conducted between February 2022 and July 2024. A total of 23 patients with small RAS-mutated thyroid nodules who underwent MWA and completed at least 12 months of follow-up were enrolled. Data on nodule volume, volume reduction rate (VRR), and MWA-related adverse events were collected. Intra-group comparisons were performed using the Friedman rank sum test with post-hoc pairwise comparisons. Factors affecting VRR were analyzed using linear regression. ROC analysis was conducted as an exploratory approach to determined the optimal diameter cut-off for predicting complete regression. Results: The cohort included 4 males (17.39%) and 19 females (82.61%), with a mean age of 45.35 ± 14.65 years. The median preoperative maximum diameter and volume were 6.20 (5.30-8.70) mm and 81.16 (46.12-256.56) mm³, respectively. All 23 patients completed ≥ 12 months of follow-up, with 6 patients reaching the 24-month follow-up. After an initial transient enlargement, the nodules showed sustained shrinkage. At the 12-month follow-up, the median VRR was 11.84% (P < 0.001), and the complete regression rate was 13.0%. By 24 months, the median VRR had reached 100%, with 83.33% complete regression (5/6). Nodules < 6 mm had higher regression rates. No local recurrence or distant metastasis occurred during the available follow-up period. Conclusion: Preliminary findings suggest that MWA may have favorable short-term efficacy and safety in the treatment of small RAS-mutated thyroid nodules.
- 22 April 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1773527
Open AccessUltrasound-guided microwave ablation for small thyroid nodules with RAS mutation: a pilot study
Objective: The clinical management of RAS-mutated nodules faces significant challenges. This study aimed to explore the efficacy of microwave ablation (MWA) for the treatment of thyroid nodules ≤ 2 cm with isolated RAS gene mutations. Methods: This retrospective study was conducted between February 2022 and July 2024. A total of 23 patients with small RAS-mutated thyroid nodules who underwent MWA and completed at least 12 months of follow-up were enrolled. Data on nodule volume, volume reduction rate (VRR), and MWA-related adverse events were collected. Intra-group comparisons were performed using the Friedman rank sum test with post-hoc pairwise comparisons. Factors affecting VRR were analyzed using linear regression. ROC analysis was conducted as an exploratory approach to determined the optimal diameter cut-off for predicting complete regression. Results: The cohort included 4 males (17.39%) and 19 females (82.61%), with a mean age of 45.35 ± 14.65 years. The median preoperative maximum diameter and volume were 6.20 (5.30-8.70) mm and 81.16 (46.12-256.56) mm³, respectively. All 23 patients completed ≥ 12 months of follow-up, with 6 patients reaching the 24-month follow-up. After an initial transient enlargement, the nodules showed sustained shrinkage. At the 12-month follow-up, the median VRR was 11.84% (P < 0.001), and the complete regression rate was 13.0%. By 24 months, the median VRR had reached 100%, with 83.33% complete regression (5/6). Nodules < 6 mm had higher regression rates. No local recurrence or distant metastasis occurred during the available follow-up period. Conclusion: Preliminary findings suggest that MWA may have favorable short-term efficacy and safety in the treatment of small RAS-mutated thyroid nodules.
- Open Access
- 14 April 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1781655
Remission rate of type 2 diabetes mellitus following multidisciplinary management in the diabetes reversal clinic and its predictive factors: a real-world study
Objective: To evaluate the effects of multidisciplinary management in the Diabetes Reversal Clinic on the remission of type 2 diabetes mellitus (T2DM), and explore the predictive factors for remission of diabetes. Methods: This was a real-world, single-arm observational study. Patients with T2DM who received remission-oriented treatment at the Diabetes Reversal Clinic and followed up regularly for more than 24 weeks were included. The primary outcome was the remission rate of T2DM, and the secondary outcomes were changes in fasting blood glucose (FBG), 2-hour postprandial blood glucose, HbA1c, blood lipids, and body composition. Differences in clinical characteristics between the remission and non-remission groups were analyzed. The multivariate logistic regression analysis was performed to screen predictive factors. Results: The remission rate was 29.24% (50/171) after multidisciplinary management in the Diabetes Reversal Clinic. The remission group was younger, had a shorter duration of diabetes, used fewer types of medications at baseline, had a lower FBG and HbA1c, a higher β-cell function index HOMA-β, and a lower triglyceride level. The multivariate logistic regression analysis revealed that age (OR = 0.93, 95% CI: 0.89-0.97, P = 0.002), type of medications at baseline (OR = 0.45, 95% CI: 0.26-0.77, P = 0.004), baseline FBG (OR = 0.64, 95% CI: 0.46-0.89, P = 0.008), and weight loss magnitude (OR = 1.15, 95% CI: 1.01-1.31, P = 0.038) were independent predictors of T2DM remission. Conclusion: In this real-world study, the remission rate of T2DM patients who visited the Diabetes Reversal Clinic for more than 24 weeks was 29.24% (50/171). Younger age, shorter disease duration, fewer baseline medications, lower FBG and HbA1c, higher HOMA-β, lower triglycerides, and greater weight loss were associated with remission of T2DM. Among them, age, baseline medication type, baseline FBG, and weight loss were identified as factors independently associated with remission. However, due to the single-arm observational design, causality cannot be established, and further prospective controlled trials are required to confirm these findings.
- 14 April 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1781655
Open AccessRemission rate of type 2 diabetes mellitus following multidisciplinary management in the diabetes reversal clinic and its predictive factors: a real-world study
Objective: To evaluate the effects of multidisciplinary management in the Diabetes Reversal Clinic on the remission of type 2 diabetes mellitus (T2DM), and explore the predictive factors for remission of diabetes. Methods: This was a real-world, single-arm observational study. Patients with T2DM who received remission-oriented treatment at the Diabetes Reversal Clinic and followed up regularly for more than 24 weeks were included. The primary outcome was the remission rate of T2DM, and the secondary outcomes were changes in fasting blood glucose (FBG), 2-hour postprandial blood glucose, HbA1c, blood lipids, and body composition. Differences in clinical characteristics between the remission and non-remission groups were analyzed. The multivariate logistic regression analysis was performed to screen predictive factors. Results: The remission rate was 29.24% (50/171) after multidisciplinary management in the Diabetes Reversal Clinic. The remission group was younger, had a shorter duration of diabetes, used fewer types of medications at baseline, had a lower FBG and HbA1c, a higher β-cell function index HOMA-β, and a lower triglyceride level. The multivariate logistic regression analysis revealed that age (OR = 0.93, 95% CI: 0.89-0.97, P = 0.002), type of medications at baseline (OR = 0.45, 95% CI: 0.26-0.77, P = 0.004), baseline FBG (OR = 0.64, 95% CI: 0.46-0.89, P = 0.008), and weight loss magnitude (OR = 1.15, 95% CI: 1.01-1.31, P = 0.038) were independent predictors of T2DM remission. Conclusion: In this real-world study, the remission rate of T2DM patients who visited the Diabetes Reversal Clinic for more than 24 weeks was 29.24% (50/171). Younger age, shorter disease duration, fewer baseline medications, lower FBG and HbA1c, higher HOMA-β, lower triglycerides, and greater weight loss were associated with remission of T2DM. Among them, age, baseline medication type, baseline FBG, and weight loss were identified as factors independently associated with remission. However, due to the single-arm observational design, causality cannot be established, and further prospective controlled trials are required to confirm these findings.
- Open Access
- 1 April 2026
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 19, 1-12
Short-Term Efficacy and Safety of Haizao Yuhu Decoction Plus Methimazole versus Methimazole Monotherapy for Graves’ Disease: A Prospective Study Using Propensity Score-Matching
To investigate the efficacy and safety of the early addition of Haizao Yuhu Decoction (HYD) with methimazole (MMI) versus the monotherapy of MMI in treating Graves’ disease (GD). This was a prospective observational study. A total of 198 patients with GD were assigned to either the HYD combined with MMI group or the MMI monotherapy group according to clinical judgment and patient preference. To minimize confounding bias, propensity score matching (PSM) was performed to balance baseline characteristics between the two groups. Primary (thyroid function, MMI dose) and secondary outcomes (general conditions, thyrotrophin receptor antibody [TRAb], thyroid size, peak systolic velocity of the superior thyroid artery [STA-PSV], the Thyroid-related Patient-Reported Outcome 39 [ThyPRO39] scores, traditional Chinese medicine [TCM] syndrome scores, and safety) were measured at 0 (V1), 4 (V2), 8 (V3) and 12 weeks of treatment (V4). Each group consisted of 54 GD patients after a 1:1 PSM. A greater decline in free thyroxine (FT4) (16.67 [7.64, 24.43] pmol/L vs 9.82 [3.49, 19.02] pmol/L, P = 0.018) and free triiodothyronine (FT3) (5.32 [3.10, 10.33] pmol/L vs 3.46 [1.16, 7.63] pmol/L, P = 0.043) was observed at V2 in the combination group than in the MMI group. The cumulative dose of MMI during the 12-week treatment was significantly lower in the combination group than in the MMI group (814.20 [600.00, 1050.00] mg vs 1007.10 [782.10, 1125.00] mg, P = 0.004). The combination group showed more pronounced reductions in the STA-PSV, TCM syndrome scores, and ThyPRO scores (P = 0.032, 0.010, and 0.044, respectively). The cumulative incidence of adverse events in the combination group was significantly lower than that in the MMI group (5.56% [3/54] vs 18.52% [10/54], P = 0.038). The combination of HYD and MMI serves as an effective and safe treatment of GD, accelerating thyroid function recovery, reducing thyroid hormone levels and ATD dosage, alleviating hyperthyroid symptoms, and lowering the risk of adverse events.
- 1 April 2026
- Published by Taylor & Francis in International Journal of General Medicine
- Vol. ume 19, 1-12
Open AccessShort-Term Efficacy and Safety of Haizao Yuhu Decoction Plus Methimazole versus Methimazole Monotherapy for Graves’ Disease: A Prospective Study Using Propensity Score-Matching
To investigate the efficacy and safety of the early addition of Haizao Yuhu Decoction (HYD) with methimazole (MMI) versus the monotherapy of MMI in treating Graves’ disease (GD). This was a prospective observational study. A total of 198 patients with GD were assigned to either the HYD combined with MMI group or the MMI monotherapy group according to clinical judgment and patient preference. To minimize confounding bias, propensity score matching (PSM) was performed to balance baseline characteristics between the two groups. Primary (thyroid function, MMI dose) and secondary outcomes (general conditions, thyrotrophin receptor antibody [TRAb], thyroid size, peak systolic velocity of the superior thyroid artery [STA-PSV], the Thyroid-related Patient-Reported Outcome 39 [ThyPRO39] scores, traditional Chinese medicine [TCM] syndrome scores, and safety) were measured at 0 (V1), 4 (V2), 8 (V3) and 12 weeks of treatment (V4). Each group consisted of 54 GD patients after a 1:1 PSM. A greater decline in free thyroxine (FT4) (16.67 [7.64, 24.43] pmol/L vs 9.82 [3.49, 19.02] pmol/L, P = 0.018) and free triiodothyronine (FT3) (5.32 [3.10, 10.33] pmol/L vs 3.46 [1.16, 7.63] pmol/L, P = 0.043) was observed at V2 in the combination group than in the MMI group. The cumulative dose of MMI during the 12-week treatment was significantly lower in the combination group than in the MMI group (814.20 [600.00, 1050.00] mg vs 1007.10 [782.10, 1125.00] mg, P = 0.004). The combination group showed more pronounced reductions in the STA-PSV, TCM syndrome scores, and ThyPRO scores (P = 0.032, 0.010, and 0.044, respectively). The cumulative incidence of adverse events in the combination group was significantly lower than that in the MMI group (5.56% [3/54] vs 18.52% [10/54], P = 0.038). The combination of HYD and MMI serves as an effective and safe treatment of GD, accelerating thyroid function recovery, reducing thyroid hormone levels and ATD dosage, alleviating hyperthyroid symptoms, and lowering the risk of adverse events.
- Open Access
- 28 January 2026
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 43 (1) , 2606698
2024 International expert consensus on ultrasound-guided thermal ablation for secondary and tertiary hyperparathyroidism
Treatments for secondary and tertiary hyperparathyroidism (SHPT/THPT) remain significant challenges in patients with end-stage renal disease. Thermal ablation (TA) has emerged as a minimally invasive, safe, and effective alternative to surgical resection (SR). However, technical variations and a lack of standardization have limited its widespread adoption. To address these challenges, an international expert panel developed consensus recommendations using a modified Delphi method, integrated with a systematic literature review. As a result, sixteen recommendations were formulated, addressing diagnosis, preoperative preparation, technical procedures, postoperative management, follow-up strategies, efficacy assessment, and complications associated with TA for SHPT/THPT. These recommendations aim to promote standardized treatment protocols, improve procedural safety, and provide evidence-based guidance for clinical practice and future research in ultrasound-guided TA for SHPT/THPT management.
- 28 January 2026
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 43 (1) , 2606698
Open Access2024 International expert consensus on ultrasound-guided thermal ablation for secondary and tertiary hyperparathyroidism
Treatments for secondary and tertiary hyperparathyroidism (SHPT/THPT) remain significant challenges in patients with end-stage renal disease. Thermal ablation (TA) has emerged as a minimally invasive, safe, and effective alternative to surgical resection (SR). However, technical variations and a lack of standardization have limited its widespread adoption. To address these challenges, an international expert panel developed consensus recommendations using a modified Delphi method, integrated with a systematic literature review. As a result, sixteen recommendations were formulated, addressing diagnosis, preoperative preparation, technical procedures, postoperative management, follow-up strategies, efficacy assessment, and complications associated with TA for SHPT/THPT. These recommendations aim to promote standardized treatment protocols, improve procedural safety, and provide evidence-based guidance for clinical practice and future research in ultrasound-guided TA for SHPT/THPT management.
- Open Access
- 26 January 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (2)
Novel ThyPRO-39-based nomogram for identifying impaired quality of life in Graves’ hyperthyroidism outpatients: development and internal validation
Objective: To identify factors independently associated with quality-of-life (QoL) impairment in Graves’ hyperthyroidism (GH) patients and develop a clinically applicable nomogram for outpatient settings. Methods: A total of 402 GH patients were recruited from the outpatient clinic of Endocrinology Department of Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, from January 2024 to June 2025. Participants were surveyed using a general information questionnaire, the Thyroid-specific Patient-Reported Outcome Short-Form (ThyPRO-39), the Pittsburgh Sleep Quality Index (PSQI), the Hamilton Depression Scale (HAMD), and the Hamilton Anxiety Scale (HAMA). Univariate and multivariate analyses identified independent predictors of QoL impairment. A nomogram was developed and validated using the area under the receiver operating characteristic curve (AUC), bootstrap-calibrated plots, and decision curve analysis (DCA). An online dynamic calculator (dynnom) was also developed to facilitate clinical application. Results: Multivariate analysis revealed that thyroid eye disease (TED), goiter, sleep disturbances, anxiety, and depressive symptoms were independent predictors of QoL impairment. The nomogram demonstrated an excellent discriminative ability: AUC was 0.886 in the training group and 0.844 in the validation group. Bootstrap calibration showed good consistency between predicted and observed probabilities. DCA revealed favorable net clinical benefit across a 0.2–0.6 threshold range. The associated online calculator further improved clinical usability. Conclusions: The nomogram integrating TED, goiter, sleep, and emotional factors provides a reliable tool for early identification of GH patients at high risk of QoL impairment in outpatient settings. Future external multicenter validation is needed to improve its generalizability.
- 26 January 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (2)
Open AccessNovel ThyPRO-39-based nomogram for identifying impaired quality of life in Graves’ hyperthyroidism outpatients: development and internal validation
Objective: To identify factors independently associated with quality-of-life (QoL) impairment in Graves’ hyperthyroidism (GH) patients and develop a clinically applicable nomogram for outpatient settings. Methods: A total of 402 GH patients were recruited from the outpatient clinic of Endocrinology Department of Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, from January 2024 to June 2025. Participants were surveyed using a general information questionnaire, the Thyroid-specific Patient-Reported Outcome Short-Form (ThyPRO-39), the Pittsburgh Sleep Quality Index (PSQI), the Hamilton Depression Scale (HAMD), and the Hamilton Anxiety Scale (HAMA). Univariate and multivariate analyses identified independent predictors of QoL impairment. A nomogram was developed and validated using the area under the receiver operating characteristic curve (AUC), bootstrap-calibrated plots, and decision curve analysis (DCA). An online dynamic calculator (dynnom) was also developed to facilitate clinical application. Results: Multivariate analysis revealed that thyroid eye disease (TED), goiter, sleep disturbances, anxiety, and depressive symptoms were independent predictors of QoL impairment. The nomogram demonstrated an excellent discriminative ability: AUC was 0.886 in the training group and 0.844 in the validation group. Bootstrap calibration showed good consistency between predicted and observed probabilities. DCA revealed favorable net clinical benefit across a 0.2–0.6 threshold range. The associated online calculator further improved clinical usability. Conclusions: The nomogram integrating TED, goiter, sleep, and emotional factors provides a reliable tool for early identification of GH patients at high risk of QoL impairment in outpatient settings. Future external multicenter validation is needed to improve its generalizability.
- Open Access
- 30 December 2025
- Published by EWA Publishing in Journal of Clinical Technology and Theory
- Vol. 4 (1) , 61-71
Research progress of traditional Chinese medicine in the treatment of benign thyroid nodules
Thyroid nodules are common diseases of the endocrine system, which belong to the category of "goiter" in Traditional Chinese Medicine (TCM). The TCM treatment of benign thyroid nodules takes syndrome differentiation and treatment as the core, forming a multi-therapy system including oral administration of Chinese herbal medicine and external treatment, with continuous deepening of relevant research and application. This paper systematically sorts out the clinical application status of various characteristic TCM therapies in the treatment of benign thyroid nodules, and looks forward to the prospects around the optimization of clinical diagnosis and treatment and the explanation of mechanisms of action, aiming to provide ideas for the TCM treatment of benign thyroid nodules.
- 30 December 2025
- Published by EWA Publishing in Journal of Clinical Technology and Theory
- Vol. 4 (1) , 61-71
Open AccessResearch progress of traditional Chinese medicine in the treatment of benign thyroid nodules
Thyroid nodules are common diseases of the endocrine system, which belong to the category of "goiter" in Traditional Chinese Medicine (TCM). The TCM treatment of benign thyroid nodules takes syndrome differentiation and treatment as the core, forming a multi-therapy system including oral administration of Chinese herbal medicine and external treatment, with continuous deepening of relevant research and application. This paper systematically sorts out the clinical application status of various characteristic TCM therapies in the treatment of benign thyroid nodules, and looks forward to the prospects around the optimization of clinical diagnosis and treatment and the explanation of mechanisms of action, aiming to provide ideas for the TCM treatment of benign thyroid nodules.
- Open Access
- 26 October 2025
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 42 (1) , 2569716
Long-term efficacy of ultrasound-guided radiofrequency and microwave ablation for benign thyroid nodules and a nomogram to predict the regrowth
To assess the long-term efficacy of ultrasound-guided radiofrequency ablation (RFA) and microwave ablation (MWA) in treating benign thyroid nodules (BTNs) and to establish a nomogram predicting post-ablation regrowth. This multi-center retrospective study included 611 patients with 753 BTNs treated by thermal ablation and followed for ≥24 months. Linear regression was used to identify factors affecting volume reduction rate (VRR). Univariate and multivariate Cox regression were performed to determine predictors of regrowth, which were incorporated into a predictive nomogram validated by calibration, concordance index (C-index), ROC, and decision curve analysis (DCA). All BTNs with a median follow-up of 36 months, nodules showed progressive shrinkage, with VRR >75% at 12 months and stabilizing near 90% by 24 months. At 60 months, the median VRR was 88.46%, with no significant difference between MWA and RFA (p > 0.05). Regrowth occurred in 6.51% (49/753) of nodules, and most were successfully retreated. Baseline maximum diameter was the only factor associated with VRR (p = 0.014). Independent predictors of regrowth included age (HR = 0.951, 95% CI: 0.909-0.994), baseline maximum diameter (HR = 1.628, 95% CI: 1.112-2.382), and energy per unit volume (HR = 0.994, 95% CI: 0.991-0.997). The nomogram demonstrated excellent performance (C-index 0.908 training, 0.792 validation), with calibration, ROC, and DCA confirming predictive accuracy and clinical utility. RFA and MWA demonstrated durable long-term efficacy and favorable safety profiles in the treatment of BTNs, with approximately 6% of nodules developing regrowth during follow-up. A nanogram is established to predict the regrowth risk.
- 26 October 2025
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 42 (1) , 2569716
Open AccessLong-term efficacy of ultrasound-guided radiofrequency and microwave ablation for benign thyroid nodules and a nomogram to predict the regrowth
To assess the long-term efficacy of ultrasound-guided radiofrequency ablation (RFA) and microwave ablation (MWA) in treating benign thyroid nodules (BTNs) and to establish a nomogram predicting post-ablation regrowth. This multi-center retrospective study included 611 patients with 753 BTNs treated by thermal ablation and followed for ≥24 months. Linear regression was used to identify factors affecting volume reduction rate (VRR). Univariate and multivariate Cox regression were performed to determine predictors of regrowth, which were incorporated into a predictive nomogram validated by calibration, concordance index (C-index), ROC, and decision curve analysis (DCA). All BTNs with a median follow-up of 36 months, nodules showed progressive shrinkage, with VRR >75% at 12 months and stabilizing near 90% by 24 months. At 60 months, the median VRR was 88.46%, with no significant difference between MWA and RFA (p > 0.05). Regrowth occurred in 6.51% (49/753) of nodules, and most were successfully retreated. Baseline maximum diameter was the only factor associated with VRR (p = 0.014). Independent predictors of regrowth included age (HR = 0.951, 95% CI: 0.909-0.994), baseline maximum diameter (HR = 1.628, 95% CI: 1.112-2.382), and energy per unit volume (HR = 0.994, 95% CI: 0.991-0.997). The nomogram demonstrated excellent performance (C-index 0.908 training, 0.792 validation), with calibration, ROC, and DCA confirming predictive accuracy and clinical utility. RFA and MWA demonstrated durable long-term efficacy and favorable safety profiles in the treatment of BTNs, with approximately 6% of nodules developing regrowth during follow-up. A nanogram is established to predict the regrowth risk.